Peregrine Pharmaceuticals (PPHM) has been under a strong bear grip, hence the stock is down -3.06% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.83% in the past 1 week. The stock has risen by 0.17% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.26% in the past 4 weeks.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.91% and the fifty day Moving Average is 5.53%. Peregrine Pharmaceuticals, Inc. has dropped 12.44% during the last three month period . Year-to-Date the stock performance stands at -69.32%.
Peregrine Pharmaceuticals (PPHM) stock is expected to deviate a maximum of $0.5 from the average target price of $1 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $2 and the most muted being $1.
Peregrine Pharmaceuticals (NASDAQ:PPHM): On Fridays trading session , Opening price of the stock was $0.36 with an intraday high of $0.3638. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.355. However, the stock managed to close at $0.359, a loss of 0.28% for the day. On the previous day, the stock had closed at $0.36. The total traded volume of the day was 553,772 shares.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.